- Education, Training & Outreach
- Patients & Caregivers
- For Investigators
- News on Dementia
- Media Room
- Donate & Contact
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001) in Patients with Mild to Moderate Alzheimer's Disease
The purpose of this clinical trial is to evaluate the efficacy and safety of Bapineuzumab, a drug that has the potential to treat Alzheimer's disease. Bapineuzumab is a vaccine against amyloid (the protein deposits in the brain that are believed to cause Alzheimer's disease). It is hoped that Bapineuzumab will attach to the amyloid protein in the brain and help the body to remove it and in doing so help stop the progression of Alzheimer's disease.
WHO IS ELIGIBLE?
We are looking for participants who:
--have been diagnosed with mild-moderate Alzheimer's disease
--are between the age of 50 and 88
--have a reliable caregiver or family member who is able to accompany them to study visits
--are in stable medical condition
--are willing to undergo genetic testing
--are willing to undergo MRI scans
People taking approved Alzheimer's medications (donepezil/Aricept, galantamine/Razadyne, rivastigmine/Exelon, memantine/Namenda) are eligible to participate in this study and can continue taking these medications during the study.
More information is attached.
Caroline A. Sullivan, BA
|3000-3001 formatted for website.doc||39 KB|